Invivyd Q1 Earnings Call Highlights
Invivyd (NASDAQ:IVVD) said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to its VYD2311 development efforts. On the company’s earnings call, Chairman Marc Elia said Invivyd’
MarketBeat ·